30 -

30 - Herrmann E, Bierer S, Gerss J, Kopke T, Hertle L, Wulfing C. Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients. Oncology. 2008;74(3-4):216-22.